BNCT Platform (Boron-10 Drug + Alphabeam™ System)
Recurrent, invasive, untreatable, and metastatic cancers (e.g., head and neck, glioblastoma)
Key Facts
About TAE Life Sciences
TAE Life Sciences is pioneering the clinical and commercial development of Boron Neutron Capture Therapy (BNCT), a two-component targeted radiotherapy. The company is building an integrated platform comprising a boron-10 drug and the Alphabeam™ in-hospital neutron generator to treat recurrent, invasive, and metastatic cancers. As a pre-revenue, private company, TAE Life Sciences is advancing its technology through development and regulatory pathways, targeting a significant unmet need in oncology with a potentially curative, single-session treatment. Its success hinges on clinical validation, regulatory approval, and establishing a new treatment paradigm within radiation oncology.
View full company profile